

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

The patient must have **ONE** of the following:

1. Non-small cell lung cancer (NSCLC)

AND the following:

- a. Metastatic disease with a positive EGFR mutation (exon 19 deletions OR exon 21 L858R substitution mutations) detected by an FDA-approved test (e.g. cobas® EGFR Mutation Test)

2. Pancreatic cancer

- a. Tumor is locally advanced, unresectable or metastatic
- b. First line treatment
- c. Used in combination with gemcitabine

3. Renal cell carcinoma

- a. Relapsed or unresectable Stage IV disease with non-clear cell histology

4. Recurrent Chordoma

5. Leptomeningeal metastases from NSCLC

- a. Positive EGFR mutation (exon 19 deletions or exon 21 L858R substitution mutations) detected by an FDA-approved test (e.g. cobas® EGFR Mutation Test)

Prior - Approval Limits

Quantity

Strength	Quantity
25 mg	180 tablets per 90 days OR
100 mg	90 tablets per 90 days OR

150 mg

90 tablets per 90 days

Maximum daily limit of any combination: 150 mg**Duration** 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Metastatic non-small cell lung cancer (NSCLC)
2. Pancreatic cancer
3. Renal cell carcinoma
4. Recurrent Chordoma
5. Leptomeningeal metastases from NSCLC

AND ALL of the following:

- a. **NO** disease progression or unacceptable toxicity

Prior - Approval *Renewal* Limits

Same as above